Nav: Home

Designing gene therapy

March 31, 2016

Scientists at EMBL have increased the efficiency of a genome-engineering tool called Sleeping Beauty, which is showing promise in clinical trials of therapies for leukaemia and lymphoma. In a study published today in Nature Communications, they reveal structural information that they hope will ultimately result in better patient outcomes.

"Based on the structure, we designed new variants that are already 30% more efficient than the most efficient ones currently available," says Orsolya Barabas, who led the work at EMBL. "That may not sound like a lot, but for patients with only a few months' prognosis, waiting 3 weeks for a treatment is better than waiting a whole month."

Sleeping Beauty is a transposon, or 'jumping gene', currently being used in clinical trials for B-cell leukaemias and lymphomas. In these treatments, Sleeping Beauty is used to insert a gene into T-cells - white blood cells that help to track down and eliminate threats such as disease-causing microbes - harvested from a patient. The genetically modified T-cells are injected back into the patient, where their new gene enables them to seek out and destroy the cancer cells. The technique is cheaper and easier to apply than current approaches, which mainly rely on modified viruses as deliverymen, so it is rapidly moving into clinical practice, and attracting investment from the pharmaceutical industry.

A bottleneck of this method is that it takes time to engineer and select the therapeutic T-cells. The quicker the T-cells can be modified and transplanted back, the better the treatment prognosis for the patients, and the lower the costs. Until now, however, efforts to increase the treatment's efficiency were educated guesses, based on the structure of similar molecules. Franka Voigt, a postdoc in Barabas' lab, determined the structure of Sleeping Beauty's active domain. Working with Zoltán Ivics' lab at the Paul Ehrlich Institute in Germany, the EMBL scientists then designed changes to that structure to make it work better.

More efficient than CRISPR

Transposons like Sleeping Beauty have advantages for therapies that hinge on inserting a gene, compared to other genome engineering approaches such as CRISPR/Cas9. Researchers can make CRISPR/Cas9 cut the genome at a specific point - making it ideal for eliminating genetic errors - but it doesn't insert any genetic material; the gene is added separately, and is only one of several options available to the cell's machinery to repair the cut. By contrast, Sleeping Beauty inserts the extra genetic material directly into the genome - and the EMBL scientists' enhancements now make it even more efficient.

"Ideally, you'd want to combine the targeting of CRISPR and the efficiency of Sleeping Beauty - but that's proving very, very difficult," says Barabas, "so it makes sense to pursue the applications that each is best at, at least for the time being."

Efforts to direct Sleeping Beauty to insert its cargo at specific locations have so far been unsuccessful. It inserts the extra genetic material at random, so there is a risk - albeit a small one - that the addition could disrupt the cell's genome. To minimise this risk, the therapies currently being trialled involve carefully selecting which T-cells to inject back into a patient, which takes time.

The scientists are continuing to design mutations to try to increase Sleeping Beauty's efficiency even further. In parallel, Barabas' lab strives to uncover the structure of the whole molecule bound to the DNA that it acts upon, as this could provide insights for further improvements. Such future improvements could make Sleeping Beauty-based therapies feasible for other conditions such as solid tumours, where the current versions of Sleeping Beauty are not efficient enough.
-end-


European Molecular Biology Laboratory

Related Genome Articles:

A close look into the barley genome
An international consortium, with the participation of the Helmholtz Zentrum München, Plant Genome and Systems Biology Department (PGSB), has published methodologically significant data on the barley genome.
Barley genome sequenced
Looking for a better beer or single malt Scotch whiskey?
From Genome Research: Pathogen demonstrates genome flexibility in cystic fibrosis
Chronic lung infections can be devastating for patients with cystic fibrosis (CF), and infection by Burkholderia cenocepacia, one of the most common species found in cystic fibrosis patients, is often antibiotic resistant.
A three-dimensional map of the genome
Cells face a daunting task. They have to neatly pack a several meter-long thread of genetic material into a nucleus that measures only five micrometers across.
Rhino genome results
A study by San Diego Zoo Global reveals that the prospects for recovery of the critically endangered northern white rhinoceros -- of which only three individuals remain -- will reside with the genetic resources that have been banked at San Diego Zoo Global's Frozen Zoo®.
More Genome News and Genome Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Teaching For Better Humans
More than test scores or good grades — what do kids need to prepare them for the future? This hour, guest host Manoush Zomorodi and TED speakers explore how to help children grow into better humans, in and out of the classroom. Guests include educators Olympia Della Flora and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#535 Superior
Apologies for the delay getting this week's episode out! A technical glitch slowed us down, but all is once again well. This week, we look at the often troubling intertwining of science and race: its long history, its ability to persist even during periods of disrepute, and the current forms it takes as it resurfaces, leveraging the internet and nationalism to buoy itself. We speak with Angela Saini, independent journalist and author of the new book "Superior: The Return of Race Science", about where race science went and how it's coming back.